Strong potential for POLB 001 to be a blockbuster treatment for severe influenza Key Highlights · POLB 001 resulted in a highly significant reduction in p38 MAP kinase driven cytokines · POLB 001 treatment exhibited a marked reduction in multiple markers of systemic and local inflammation compared with placebo · Trial results demonstrate expected utility in severe influenza […]
Aeroject™ 3ml safety syringe is a single-use, affordable, first generation syringe Aeroject™ has a permanently attached needle system, which upon retraction, fully encases the needle, preventing needle reuse and accidental needlestick The ultra-low wasted space syringes allow for the maximum number of doses to be administered per vial, lowering costs 16 February 2023 – Vancouver, Canada: […]
14 February 2023 – Optimum Strategic Communications (“Optimum”), the specialist life sciences communications consultancy, today announces that it has hired Jonathan Edwards and Hana Malik, two highly experienced investor relations and communications professionals, to join as permanent members of its team. Edwards and Malik have joined Optimum as Account Directors and will be advising clients across […]
The Novo Holdings Venture Investments team has published its 2023 newsletter today. It is one of the largest and most active international life science venture investors with a track record of over 20 years investing in novel therapies. For more information, please see Venture Investments 2023 Newsletter.
alfapump® – successful primary endpoint read-out of North American pivotal POSEIDON study / PMA[1] filing planned for H2 2023 DSR® (Direct Sodium Removal) – clinical evidence of disease-modifying heart failure drug therapy, on track to start US Phase 1/2a MOJAVE study in Q2 2023 Total cash position of €18.9 million at end 2022 and cash runway […]